Cardiology and Cardiovascular Research

Research Article | | Peer-Reviewed |

Pulmonary Arterial Hypertension: Epidemiological, Clinical Aspects and Prognoses in the Cardiology Department and Internal Medicine of CHU Brazzaville

Received: 15 December 2023    Accepted: 27 December 2023    Published: 18 January 2024
Views:       Downloads:

Share This Article

Abstract

Pulmonary Arterial Hypertension PAH is a medical condition serious and severe. In Congo, its epidemiology and its etiologies are poorly understood. This study, aimed at improving the care of patients with PAH, was interested to epidemio-clinical aspects, and prognosis of this entity. This was a retrospective, cross-sectional study carried out from the 1st January 2021 to December 31, 2022 (2 years) in Brazzaville University Hospital. Were included 148 patients, the diagnostic criteria having permit to retain a PAH were compliant to that of the PAPUCO study (PAH if PAPS ≥ 35 mmHg, severe PAH if PAPS ≥ 60 mmHg). The heart failure syndrome was present in 140 cases (94.6%), it was right exclusively in 36 cases (24.3%). The etiologies of the group, they were present in 97 cases (66%) followed group III in 24 cases (16.2%). PAH was said to be severe in 39 cases (26.3%). The evolution has been towards complications in 29 cases (19.6%), lethality in 17 cases (11.5%). Poor prognosis factors were the existence of underlying heart disease underlying (AOR =5.6; p =0.02), male sex (AOR=4.8; p=0.02); hyperkalemia (AOR= 9.4; p=0.00). High blood pressure pulmonary is an increasingly common condition encountered in clinical practice in our context.

DOI 10.11648/j.ccr.20240801.11
Published in Cardiology and Cardiovascular Research (Volume 8, Issue 1, April 2024)
Page(s) 1-6
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

PAH, Left Heart Disease, Brazzaville, Congo

References
[1] Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 11 oct 2022; 43(38): 3618 731.
[2] Collège national des enseignants de cardiologie et de la société française. Cardiologie. 2E édition ELSEVIER MASSON, Paris 2015; 284 P.
[3] Thienemann F, Dzudie A, Mocumbi AO, et al. Rationale and design of the Pan African Pulmonary hypertension Cohort (PAPUCO) study: implementing a contemporary registry on pulmonary hypertension in Africa. BMJ Open. 2014; 4(10): e005950.
[4] Galiè N, Humbert M, Vachiery JL, et al: 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37(1): 67-119, 2016.
[5] Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2022; 2200879.
[6] Jingi AM, Noubiap JJ et al. Prevalence and determinants of pulmonary hypertension in a group of Cameroonian patients without chronic lung disease: a cross-sectional echocardiographic study. BMC Res Notes 2017; 10: 571.
[7] Koné A, Koffi MOB, Samaké K, Djegbeton A, Kouraogo BW, Mobio LNA, et al. Difficulties in the management of pulmonary hypertension in a pneumology department in Abidjan, Côte d'Ivoire. Revue des Maladies Respiratoires Actualités. 2023; 15(1): 211 2.
[8] Balola MB, Mateso GQM, Munyerenkana RB, Nzabara F, Maheshe G. Causes of pulmonary hypertension in South Kivu, case of Bukavu Provincial General Reference Hospital. Ann afr méd (Online). 2020; 3829 39.
[9] Ovaga BE. Exclusive right heart failure in the Department of Cardiology and Internal Medicine at Brazzaville University Hospital. Thèse de Médecine. Université Marien Ngouabi; 2016, 74P. v.
[10] Simonneau G, Moutari D et al. Haemodynamic definitions and updated Clinical classification of pulmonary hypertension. Eur Respir J 2019; 53: 1801913.
[11] Rochon ER, Krowka MJ, Bartolome S, et al: BMP 9/10 in pulmonary vascular complications of liver disease. Am J Respir Crit Care Med 201(11): 1575–1578, 2020. doi: 10.1164/rccm.201912-2514LE.
[12] Beghetti M, Simonneau G. Classification de l’hypertension artérielle pulmonaire. Arch Cardiol Desease 2010; 2: 132-136.
[13] Reinero C, Visser LC, Kellihan HB, Masseau I, Rozanski E, Clercx C, et al. ACVIM consensus statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary hypertension in dogs. J Vet Intern Med. mars 2020; 34(2): 549 73.
[14] Choudhary G, Jankowich M. Prevalence and Clinical Characteristics Associated with Pulmonary Hypertension in African-Americans. PloS One. 2013. 8(12): e84264.
[15] Enea I, Ghio S et al. Echocardiographic alterations suggestive of pulmonary hypertension in the italian ultrasonography laboratories. Epidemiological data from the INCIPT study. G Ital Cardiol. Rome. 2010. 11: 402-407.
[16] Sobanski V, Sanges S, Launay D, Humbert M. Hypertension pulmonaire et connectivites. Revue du rhumatisme monographies. 2018; 85(3): 210 20.
[17] Badesch DB, Raskob GE. Pulmonary arterial hypertension: Baseline charactéristics from the REVEAL registry. Chest 2010: 137(2): 376-387.
[18] Dzudie A et al. Pulmonary hypertension as seen in a rural area in sub-Saharan Africa: high prevalence, late clinical presentation and a high short-term mortality rate during follow up. Cardiovasc J Afr 2018; 29(4): 208-212.
[19] Ngunga M et al. Long-Term Outcomes and Factors Associated with Mortality in Patients with Moderate to Severe Pulmonary Hypertension in Kenya. Global Heart. 2020; 15(1); 6.
[20] Vachiéry JL, Tedford RJ, Rosenkranz S, Palazzini M, Lang I, Guazzi M, et al. Pulmonary hypertension due to left heart disease. Eur Respir J. janv 2019; 53(1): 1801897.
[21] Ikama SM et al. Epidemiological and clinical profile of dilated cardiomyopathy at the Centre Hospitalier Universitaire de Brazzaville, Congo. Pan African Medical Journal. 2018; 31: 164.
[22] Cassady SJ, Ramani GV. Right Heart Failure in Pulmonary Hypertension. Cardiol Clin. mai 2020; 38(2): 243 55.
[23] Cappola et al. Pulmonary hypertension and myocarditis: a higher risk of death. Circulation 2002. (https://www.caducee.net/actualité-medicale/3554/hypertension-pulmonaire-et-myocardite.html).
[24] Maloir Q, PETITJEAN H, Parzibut G, Weber T, DAVIDSEN C, Dulgheru E, et al. New developments in the diagnosis and risk stratification of pulmonary hypertension. Revue Médicale de Liège [Internet]. 2023 [cited 19 Nov 2023]; 78(2). Available from: https://orbi.uliege.be/handle/2268/300917
Cite This Article
  • APA Style

    Ngamami, S. F. M., Taty, R. J., Letomo, K. M. N., Landa, C. M. K., Naibe, G. T., et al. (2024). Pulmonary Arterial Hypertension: Epidemiological, Clinical Aspects and Prognoses in the Cardiology Department and Internal Medicine of CHU Brazzaville. Cardiology and Cardiovascular Research, 8(1), 1-6. https://doi.org/10.11648/j.ccr.20240801.11

    Copy | Download

    ACS Style

    Ngamami, S. F. M.; Taty, R. J.; Letomo, K. M. N.; Landa, C. M. K.; Naibe, G. T., et al. Pulmonary Arterial Hypertension: Epidemiological, Clinical Aspects and Prognoses in the Cardiology Department and Internal Medicine of CHU Brazzaville. Cardiol. Cardiovasc. Res. 2024, 8(1), 1-6. doi: 10.11648/j.ccr.20240801.11

    Copy | Download

    AMA Style

    Ngamami SFM, Taty RJ, Letomo KMN, Landa CMK, Naibe GT, et al. Pulmonary Arterial Hypertension: Epidemiological, Clinical Aspects and Prognoses in the Cardiology Department and Internal Medicine of CHU Brazzaville. Cardiol Cardiovasc Res. 2024;8(1):1-6. doi: 10.11648/j.ccr.20240801.11

    Copy | Download

  • @article{10.11648/j.ccr.20240801.11,
      author = {Solange Flore Mongo Ngamami and Ruddy Junior Taty and Kivie Mou-moue Ngolo Letomo and Christian Michel Kouala Landa and Gankama Thibault Naibe and Jospin Karel Makani Bassoukouahou and Rog Paterne Bakekolo and Meo Stephane Ikama and Fikahem Ellenga Mbolla},
      title = {Pulmonary Arterial Hypertension: Epidemiological, Clinical Aspects and Prognoses in the Cardiology Department and Internal Medicine of CHU Brazzaville},
      journal = {Cardiology and Cardiovascular Research},
      volume = {8},
      number = {1},
      pages = {1-6},
      doi = {10.11648/j.ccr.20240801.11},
      url = {https://doi.org/10.11648/j.ccr.20240801.11},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ccr.20240801.11},
      abstract = {Pulmonary Arterial Hypertension PAH is a medical condition serious and severe. In Congo, its epidemiology and its etiologies are poorly understood. This study, aimed at improving the care of patients with PAH, was interested to epidemio-clinical aspects, and prognosis of this entity. This was a retrospective, cross-sectional study carried out from the 1st January 2021 to December 31, 2022 (2 years) in Brazzaville University Hospital. Were included 148 patients, the diagnostic criteria having permit to retain a PAH were compliant to that of the PAPUCO study (PAH if PAPS ≥ 35 mmHg, severe PAH if PAPS ≥ 60 mmHg). The heart failure syndrome was present in 140 cases (94.6%), it was right exclusively in 36 cases (24.3%). The etiologies of the group, they were present in 97 cases (66%) followed group III in 24 cases (16.2%). PAH was said to be severe in 39 cases (26.3%). The evolution has been towards complications in 29 cases (19.6%), lethality in 17 cases (11.5%). Poor prognosis factors were the existence of underlying heart disease underlying (AOR =5.6; p =0.02), male sex (AOR=4.8; p=0.02); hyperkalemia (AOR= 9.4; p=0.00). High blood pressure pulmonary is an increasingly common condition encountered in clinical practice in our context.
    },
     year = {2024}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Pulmonary Arterial Hypertension: Epidemiological, Clinical Aspects and Prognoses in the Cardiology Department and Internal Medicine of CHU Brazzaville
    AU  - Solange Flore Mongo Ngamami
    AU  - Ruddy Junior Taty
    AU  - Kivie Mou-moue Ngolo Letomo
    AU  - Christian Michel Kouala Landa
    AU  - Gankama Thibault Naibe
    AU  - Jospin Karel Makani Bassoukouahou
    AU  - Rog Paterne Bakekolo
    AU  - Meo Stephane Ikama
    AU  - Fikahem Ellenga Mbolla
    Y1  - 2024/01/18
    PY  - 2024
    N1  - https://doi.org/10.11648/j.ccr.20240801.11
    DO  - 10.11648/j.ccr.20240801.11
    T2  - Cardiology and Cardiovascular Research
    JF  - Cardiology and Cardiovascular Research
    JO  - Cardiology and Cardiovascular Research
    SP  - 1
    EP  - 6
    PB  - Science Publishing Group
    SN  - 2578-8914
    UR  - https://doi.org/10.11648/j.ccr.20240801.11
    AB  - Pulmonary Arterial Hypertension PAH is a medical condition serious and severe. In Congo, its epidemiology and its etiologies are poorly understood. This study, aimed at improving the care of patients with PAH, was interested to epidemio-clinical aspects, and prognosis of this entity. This was a retrospective, cross-sectional study carried out from the 1st January 2021 to December 31, 2022 (2 years) in Brazzaville University Hospital. Were included 148 patients, the diagnostic criteria having permit to retain a PAH were compliant to that of the PAPUCO study (PAH if PAPS ≥ 35 mmHg, severe PAH if PAPS ≥ 60 mmHg). The heart failure syndrome was present in 140 cases (94.6%), it was right exclusively in 36 cases (24.3%). The etiologies of the group, they were present in 97 cases (66%) followed group III in 24 cases (16.2%). PAH was said to be severe in 39 cases (26.3%). The evolution has been towards complications in 29 cases (19.6%), lethality in 17 cases (11.5%). Poor prognosis factors were the existence of underlying heart disease underlying (AOR =5.6; p =0.02), male sex (AOR=4.8; p=0.02); hyperkalemia (AOR= 9.4; p=0.00). High blood pressure pulmonary is an increasingly common condition encountered in clinical practice in our context.
    
    VL  - 8
    IS  - 1
    ER  - 

    Copy | Download

Author Information
  • Health Sciences Faculty, Marien Ngouabi University, Brazzaville, Republic of Congo

  • Hospital Teaching of Brazzaville, Brazzaville, Republic of Congo

  • Hospital Teaching of Brazzaville, Brazzaville, Republic of Congo

  • Health Sciences Faculty, Marien Ngouabi University, Brazzaville, Republic of Congo

  • Hospital Teaching of Brazzaville, Brazzaville, Republic of Congo

  • Hospital Teaching of Brazzaville, Brazzaville, Republic of Congo

  • Hospital Teaching of Brazzaville, Brazzaville, Republic of Congo

  • Health Sciences Faculty, Marien Ngouabi University, Brazzaville, Republic of Congo

  • Health Sciences Faculty, Marien Ngouabi University, Brazzaville, Republic of Congo

  • Sections